about
Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapyUse of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpointPharmacodynamics of fluconazole in a murine model of systemic candidiasis.Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing.Penetration of cefetamet pivoxil and cefuroxime axetil into the maxillary sinus mucosa at steady state.In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patientsComparative bactericidal activity of ceftazidime against isolates of Pseudomonas aeruginosa as assessed in an in vitro pharmacodynamic model versus the traditional time-kill method.Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsisPharmacodynamics of intravenous ciprofloxacin in seriously ill patients.Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similarImpact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials.Setting and revising antibacterial susceptibility breakpoints.Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearanceAntibiotic tissue penetration and its relevance: impact of tissue penetration on infection response.An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions: a systematic review and meta-analysis.Role of pharmacokinetics in the outcome of infections.Modeling the response of pneumonia to antimicrobial therapy.
P2860
Q24519008-DCA10BBE-7CFA-4F94-8909-11A9EB6779D6Q30620954-4C254C32-4F9E-4846-BD2C-102B8BAC6B9EQ33695281-9C1617BD-BC21-46C2-905E-C703643407C6Q33981666-C4AB4FB0-62F7-4E7D-8F74-4C062FD99B7FQ33982552-88F5F915-F188-45A6-BF03-C08FF2FC6C3CQ35123334-401A7218-3B71-4079-ADB1-1EB81DCE6D3CQ35138316-9592D0FC-4298-4467-8B0B-2A90EC8F63BAQ35139026-EC213036-99B1-4E23-A9FE-C4A48D09D770Q35810298-343C35ED-D77A-4129-BE8C-C7C129E25FB2Q35814807-C4CDA85C-76F6-49AB-9D8E-92D20165A767Q35820123-83F5B447-8C3D-40ED-9F1E-0114AEB1828CQ35822946-7A4FC88F-D8B2-439E-802E-9302E11350E2Q35862757-F4905D7E-3325-437E-AC4B-77AA4632460EQ35913176-6E867D1A-A184-4B25-8CFB-9D266FA172CDQ36089167-4EE5AB23-3CD8-4F4B-A5E5-29950C416AE8Q36863646-1FB2DC40-3D6C-429C-9C0A-9146797FDA4DQ37563029-2F0992F6-8208-4DEF-B723-96C1DC209EC7Q38167345-96EA08E2-5A53-48D8-9F4E-8864920EA4B8Q39639407-3953685F-2223-4E93-9E87-436700477D32Q39784308-6ADDAB53-3D0F-42EE-A353-31A99D852565
P2860
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年学术文章
@wuu
1984年学术文章
@zh
1984年学术文章
@zh-cn
1984年学术文章
@zh-hans
1984年学术文章
@zh-my
1984年学术文章
@zh-sg
1984年學術文章
@yue
1984年學術文章
@zh-hant
name
Role for dual individualization with cefmenoxime.
@en
Role for dual individualization with cefmenoxime.
@nl
type
label
Role for dual individualization with cefmenoxime.
@en
Role for dual individualization with cefmenoxime.
@nl
prefLabel
Role for dual individualization with cefmenoxime.
@en
Role for dual individualization with cefmenoxime.
@nl
P2093
P1476
Role for dual individualization with cefmenoxime
@en
P2093
C DeAngelis
D J Swanson
J E Fracasso
J J Schentag
P356
10.1016/S0002-9343(84)80074-1
P407
P577
1984-12-01T00:00:00Z